{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:34:11Z","timestamp":1787697251235,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.eprac.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:06:18Z","timestamp":1650373578000},"page":"637-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly"],"prefix":"10.1016","volume":"28","author":[{"given":"Kevin C.J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4158\/EP161373.OR","article-title":"Predictors of quality of life in 165 patients with acromegaly: results from a single-center study","volume":"23","author":"Kreitschmann-Andermahr","year":"2017","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.009_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11102-011-0326-z","article-title":"Cognitive function in acromegaly: description and brain volumetric correlates","volume":"15","author":"Sievers","year":"2012","journal-title":"Pituitary"},{"issue":"24","key":"10.1016\/j.eprac.2022.04.009_bib6","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12020-018-1789-8","article-title":"Correction to: signs and symptoms of acromegaly at diagnosis: the physician's and the patient\u2019s perspectives in the ACRO-POLIS study","volume":"63","author":"Caron","year":"2019","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11102-015-0702-1","article-title":"Diagnosis and management of acromegaly: the patient's perspective","volume":"19","author":"Kreitschmann-Andermahr","year":"2016","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A\u00a0Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.009_bib12","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.009_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A\u00a0Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jocn.2010.10.003","article-title":"Treatment of persistent and recurrent acromegaly","volume":"18","author":"Del Porto","year":"2011","journal-title":"J\u00a0Clin Neurosci"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2022.04.009_bib23","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1210\/jendso\/bvab048.1073","article-title":"Safety and efficacy of switching injected peptide long-acting somatostatin receptor ligands to once daily oral paltusotine: ACROBAT Edge phase 2 study","volume":"5","author":"Gadelha","year":"2021","journal-title":"J\u00a0Endocrine Soc"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.009_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.009_bib31","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A\u00a0randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.009_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib37","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.009_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","article-title":"Pituitary tumors centers of excellence","volume":"49","author":"Frara","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2022.04.009_bib41","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2022.04.009_bib42","first-page":"1217","article-title":"Acromegaly: current therapies benefits and burdens","volume":"10","author":"Yedinak","year":"2016","journal-title":"Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.009_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.009_bib46","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.009_bib47","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.04.009_bib48","doi-asserted-by":"crossref","first-page":"A524","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J\u00a0Endocrine Soc"},{"issue":"8","key":"10.1016\/j.eprac.2022.04.009_bib49","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A\u00a0novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.009_bib53","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.009_bib54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/17425247.2021.1942838","article-title":"Transient Permeation Enhancer\u00ae (TPE\u00ae) technology for oral delivery of octreotide: a technological evaluation","volume":"18","author":"Brayden","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib55","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0016-5085(91)90651-Z","article-title":"Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization","volume":"100","author":"Fricker","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00544562","article-title":"Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage","volume":"33","author":"K\u00f6hler","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2021.1825375","article-title":"Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans","volume":"18","author":"Maher","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.eprac.2022.04.009_bib58","series-title":"Nanostructures for Oral Medicine","first-page":"435","article-title":"Recent advancements in oral delivery of insulin: from challenges to solutions","author":"Chouhan","year":"2017"},{"key":"10.1016\/j.eprac.2022.04.009_bib59","first-page":"A515","article-title":"One-year outcomes of the open-label extension of CHIASMA OPTIMAL, a phase 3 study of oral octreotide capsules in acromegaly [abstract]","volume":"5","author":"Samson","year":"2021","journal-title":"In: J Endocrine Soc"},{"key":"10.1016\/j.eprac.2022.04.009_bib60","first-page":"S131","article-title":"Effects of prior injectable somatostatin receptor ligand type and dose in patients with acromegaly receiving oral octreotide capsules in the phase 3 MPOWERED trial [abstract]","volume":"27","author":"Gordon","year":"2021","journal-title":"In: Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.04.009_bib61","doi-asserted-by":"crossref","first-page":"A518","DOI":"10.1210\/jendso\/bvab048.1058","article-title":"Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.eprac.2022.04.009_bib62","first-page":"S132","article-title":"Improved quality of life and work productivity in patients with acromegaly receiving oral octreotide capsules in the phase 3 MPOWERED trial [abstract]","volume":"27","author":"Biermasz","year":"2021","journal-title":"In: Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib63","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11102-019-00986-4","article-title":"Development of a novel patient-reported measure for acromegaly: the Acro-TSQ","volume":"22","author":"Fleseriu","year":"2019","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.009_bib64","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-16-1059","article-title":"Management of endocrine disease: acromegaly and pregnancy: a contemporary review","volume":"177","author":"Abucham","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.009_bib65","article-title":"Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating","volume":"42","author":"Babinska","year":"2021","journal-title":"Neuro Endocrinol Lett"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.009_bib66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cen.13599","article-title":"Outcome of pregnancies in a large cohort of women with acromegaly","volume":"88","author":"Jallad","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib67","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-020-02430-1","article-title":"First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly","volume":"70","author":"Vialon","year":"2020","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.009_bib68","doi-asserted-by":"crossref","first-page":"dgaa444","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.009_bib69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2015.196","article-title":"New therapeutic agents for acromegaly","volume":"12","author":"Melmed","year":"2016","journal-title":"Nat Rev Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22004888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22004888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:19Z","timestamp":1761516739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22004888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1530891X22004888"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.04.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}